Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study
The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
- The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
- Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
- Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
- Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.